Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442546 · ClinicalTrials.gov registry record · Phase 3
Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 307
- Enrollment target
NCT00442546 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 307 participants.
The verdict
NCT00442546, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 307 participants
- Enrollment target
Study Summary
Pregabalin added to the standard of care with dosing starting preoperatively and continuing for up to 6 weeks post surgery will decrease the intensity of post-operative pain following total knee replacement.
Interventions
- DRUG Placebo
- DRUG pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442546
The ClinicalTrials.gov registry entry for NCT00442546 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00442546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00442546 about?
NCT00442546 is a clinical study titled "Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement". Pregabalin added to the standard of care with dosing starting preoperatively and continuing for up to 6 weeks post surgery will decrease the intensity of post-operative pain following total knee replacement.
What is the current status of trial NCT00442546?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 307 participants. The study started on 2007-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00442546?
The interventions under investigation include: Placebo (DRUG), pregabalin (DRUG).
Who is sponsoring clinical trial NCT00442546?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.